STEREOCHEMISTRY OF PHENYLPIRACETAM AND ITS METHYL DERIVATIVE: IMPROVEMENT OF THE PHARMACOLOGICAL PROFILE

Authors

  • Grigory Veinberg Latvian Institute of Organic Synthesis, 21 Aizkraukles St., Riga LV-1006
  • Edijs Vavers Latvian Institute of Organic Synthesis
  • Natalja Orlova Latvian Institute of Organic Synthesis
  • Jevgenijs Kuznecovs Latvian Institute of Organic Synthesis
  • Ilona Domracheva Latvian Institute of Organic Synthesis
  • Maxim Vorona Latvian Institute of Organic Synthesis
  • Liga Zvejniece Latvian Institute of Organic Synthesis
  • Maija Dambrova Latvian Institute of Organic Synthesis

DOI:

https://doi.org/10.1007/2423

Keywords:

E1R, (4R, 5S)-5-methyl-2-oxo-4-phenylpyrrolidine-1-carboxamide, (4R)-2-oxo-4-phenylpyrrolidine-1-carboxamide, (R)-phenylpiracetam, nootropic activity, stereoselective pharmacological activity, stereochemical resolution

Abstract

Since the discovery of piracetam, its structural analogs based on the pyrrolidin-2-one pharmacophore have aroused great interest as a source of effective pharmacological central nervous system agents capable to facilitate memory processes and to attenuate the impairment of cognitive functions associated with head traumas, stroke, age, and age-related pathologies. The present review summarizes the data published during the last decade concerning the design, synthesis, and biological activity exploration of enantiomerically pure (4R)-2-oxo-4-phenylpyrrolidine-1-carboxamide ((R)-phenylpiracetam) and (4R,5S)-5-methyl-2-oxo-4-phenylpyrrolidine-1-carboxamide
(E1R) and providing evidence for the direct relationship between the configuration of the stereocenters and biological properties of the respective enantiomers. The methodological approaches leading to the preparation of the single stereoisomers of molecules with one or two chiral centers are reviewed. The results of comparative pharmacological testing of individual enantiomers provides the evidence of their pharmacological advantages, justifying the choice of the most effective stereoisomer and the necessity for drug substance purification from the less active one(s).

How to Cite
Veinberg, G.; Vavers, E.; Orlova, N.; Kuznecovs, J.; Domracheva, I.; Vorona, M.; Zvejniece, L.; Dambrova, M. Chem. Heterocycl. Compd. 2015, 51, 601. [Khim. Geterotsikl. Soedin. 2015, 51, 601.]

For this article in the English edition see DOI 10.1007/s10593-015-1747-9

Author Biographies

Grigory Veinberg, Latvian Institute of Organic Synthesis, 21 Aizkraukles St., Riga LV-1006

Grygory Veinberg

Principal researcher

Edijs Vavers, Latvian Institute of Organic Synthesis

Edijs Vavers

Asisstant

Natalja Orlova, Latvian Institute of Organic Synthesis

Natalja Orlova

Asisstant

Jevgenijs Kuznecovs, Latvian Institute of Organic Synthesis

Jevgenijs Kuznecovs

Asisstant

Ilona Domracheva, Latvian Institute of Organic Synthesis

Ilona Domracheva

Researcher

Maxim Vorona, Latvian Institute of Organic Synthesis

Maxim Vorona

Principal researcer

Liga Zvejniece, Latvian Institute of Organic Synthesis

Liga Zvejniece

Principal researcher

Maija Dambrova, Latvian Institute of Organic Synthesis

Maija Dambrova

Principal researcher

Published

2015-05-25

Issue

Section

Review Articles